ClinicalTrials.gov
ClinicalTrials.gov Menu

Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00518661
Recruitment Status : Active, not recruiting
First Posted : August 21, 2007
Last Update Posted : June 9, 2017
Sponsor:
Information provided by (Responsible Party):
Yohei Doi, University of Pittsburgh

Brief Summary:
This is a retrospective chart review. This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.

Condition or disease
Quinolone Resistance ESBL Klebsiella Species Infection

Detailed Description:
This is a retrospective chart review. This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed. This research is (c) important because identification of risk factors may allow earlier initiation of appropriate therapy in patients infected with these bacteria. Additionally, we will identify whether horizontal spread is responsible for this increasing trend.

Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Risk Factors for Quinolone Resistance Among Extended-Spectrum Beta-Lactamase-Producing Klebsiella Species
Study Start Date : August 2007
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine

U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
quinolone resistant
Criteria

Inclusion Criteria:

  • must be quinolone resistant among ESBL producing klebsiella species

Exclusion Criteria:

  • Those not meeting entry criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00518661


Locations
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: Brian Potoski, PharmD University of Pittsburgh

Responsible Party: Yohei Doi, Associate Professor, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00518661     History of Changes
Other Study ID Numbers: PRO07070356
investigator funding ( Other Identifier: UPMC )
First Posted: August 21, 2007    Key Record Dates
Last Update Posted: June 9, 2017
Last Verified: June 2017

Keywords provided by Yohei Doi, University of Pittsburgh:
quinolone resistance
ESBL
Klebsiella species
Infection

Additional relevant MeSH terms:
Klebsiella Infections
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections